The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide

Pharmacogenomics

Volumn 12, Issue 1, 2011, Pages 41-47

  Dziedziejko, Violetta ^a   Kurzawski, Mateusz ^a   Safranow, Krzysztof ^a   Chlubek, Dariusz ^a   Pawlik, Andrzej ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

estrogen receptors; genetic polymorphism; leflunomide; rheumatoid arthritis

Indexed keywords

ADENOSINE; CYTOSINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GUANOSINE; LEFLUNOMIDE; THYMINE;

ARTICLE; DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 78650470072     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.164     Document Type: Article

References (36)

1. Herrmann ML, Schleyerbach R, Kirschbaum BJ: Lefunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47, 273-289 (2000).
2. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA: The immunosuppressive metabolite of lefunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35, 1270-1273 (1996).
3. Litinsky I, Paran D, Levartovsky D et al.: The effects of lefunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 33, 106-110 (2006).
4. Cherwinski HM, Cohn RG, Cheung P et al.: The immunosuppressant lefunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275, 1043-1049 (1995).
5. Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M: The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with lefunomide. Pharmacogenomics 10, 303-309 (2009).
6. Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V: Dihydroorotate dehydrogenase polymorphism infuences the toxicity of lefunomide treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68, 1367-1368 (2009).
7. Kvien TK, Uhlig T, Ødegård S, Heiberg MS: Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann. NY Acad. Sci. 1069, 212-222 (2006).
8. Sokka T, Toloza S, Cutolo M et al.: Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res. Ther. 11, R7 (2009).
9. Montagna P, Brizzolara R, Soldano S, Pizzorni C, Sulli A, Cutolo M: Sex hormones and lefunomide treatment of human macrophage cultures: effects on apoptosis. Int. J. Clin. Exp. Med. 2, 221-232 (2009).
10. Montagna P, Soldano S, Brizzolara R et al.: Estrogens interfere with lefunomide modulation of cytokine production by human activated monocytes. Ann. NY Acad. Sci. 1193, 30-35 (2010).
11. Cutolo M, Brizzolara R, Atzeni F, Capellino S, Straub RH, Puttini PC: The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann. NY Acad. Sci. 1193, 36-42 (2010).
12. Moriarty K, Kim KH, Bender JR: Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 147, 5557-5563 (2006).
13. Menasce LP, White GR, Harrison CJ, Boyle JM: Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 17, 263-265 (1993).
14. Kos M, Reid G, Denger S, Gannon F: Minireview: genomic organization of the human ERa gene promoter region. Mo l. Endocrinol. 15, 2057-2063 (2001).
15. Drummond AE, Fuller PJ: The importance of ERb signalling in the ovary. J. Endocrinol. 205, 15-23 (2010).
16. Boot AM, van Der Sluis IM, de Muinck Keizer-Schrama SM et al.: Estrogen receptor a gene polymorphisms and bone mineral density in healthy children and young adults. Calcif. Tissue Int. 74, 495-500 (2004).
17. Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML: Estrogen receptor a and b polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 13, 451-461 (2006).
18. Kim JJ, Choi YM, Choung SH, Yoon SH, Lee GH, Moon SY: Estrogen receptor b gene +1730 G/A polymorphism in women with polycystic ovary syndrome. Fertil. Steril. 93, 1942-1947 (2010).
19. Felson DT, Anderson JJ, Boers M et al.: American College of Rheumatology. Preliminary defnition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727-735 (1995).
20. Fuchs HA, Brooks RH, Callahan LF, Pincus T: A simplifed twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 32, 531-537 (1989).
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modifed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44-48 (1995).
22. Ushiyama T, Mori K, Inoue K, Huang J, Nishioka J, Hukuda S: Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis. Ann. Rheum. Dis. 58, 7-10 (1999).
23. Takagi H, Ishiguro N, Iwata H, Kanamono T: Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J. Rheumatol. 27, 1638-1642 (2000).
24. Karlson EW, Chibnik LB, McGrath M et al.: A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis. Arthritis Res. Ther. 11, R97 (2009).
25. Ghosh SN, Seshadri R: Expression of tumor cell properties in synovial cells in culture. Acta Cytol. 31, 77-80 (1987).
26. Ushiyama T, Inoue K, Nishioka J: Expression of estrogen receptor related protein (p29) and estradiol binding in human arthritic synovium. J. Rheumatol. 22, 421-426 (1995).
27. Khalkhali-Ellis Z, Seftor EA, Nieva DR et al.: Estrogen and progesterone regulation of human fbroblast-like synoviocyte function in vitro: implications in rheumatoid arthritis. J. Rheumatol. 27, 1622-1631 (2000).
28. Cutolo M, Accardo S, Villaggio B et al.: Presence of estrogen-binding sites on macrophage-like synoviocytes and CD8+, CD29+, CD45RO+ T lymphocytes in normal and rheumatoid synovium. Arthritis Rheum. 36, 1087-1097 (1993).
29. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S: Macrophages, synovial tissue and rheumatoid arthritis. Clin. Exp. Rheumatol. 11, 331-339 (1993).
30. Rovensky J, Kvetnansky R, Radikova Z et al.: Hormone concentrations in synovial fuid of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 23, 292-296 (2005).
31. Capellino S, Montagna P, Villaggio B, Soldano S, Straub RH, Cutolo M: Hydroxylated estrogen metabolites infuence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin. Exp. Rheumatol. 26, 903-909 (2008).
32. Montagna P, Capellino S, Villaggio B et al.: Peritoneal fuid macrophages in endometriosis: correlation between the expression of estrogen receptors and infammation. Fertil. Steril. 90, 156-164 (2008).
33. Li WD, Ran GX, Teng HL, Lin ZB: Dynamic effects of lefunomide on IL-1, IL-6, and TNF-a activity produced from peritoneal macrophages in adjuvant arthritis rats. Acta Pharmacol. Sin. 23, 752-756 (2002).
34. Cutolo M, Montagna P, Brizzolara R et al.: Sex hormones modulate the effects of Lefunomide on cytokine production by cultures of differentiated monocyte/ macrophages and synovial macrophages from rheumatoid arthritis patients. J. Autoimmun. 32, 254-260 (2009).
35. Schuit SC, de Jong FH, Stolk L et al.: Estrogen receptor a gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur. J. Endocrinol. 153, 327-334 (2005).
36. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF Jr: Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am. J. Med. 119, S16-S22 (2006).